Clinical trial
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients…
NCT00437112 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00437112 |
|---|---|
| Title | Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes |
| Official title | A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared With Once-Daily Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Mellitus on Oral Agents |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Alkermes, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Human Insulin Inhalation Powder, Insulin Glargine |
| Enrollment | 142 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Feb 19, 2007 |
| Last update posted | Mar 9, 2018 |
| Countries | Brazil, India, Puerto Rico, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: